, Volume 124, Issue 3, pp 261–266 | Cite as

Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans

  • S. Rockstroh
  • M. Emre
  • R. Pokorny
  • A. Tarral
Original Investigation


Effects of the novel competitiveN-methyl-d-aspartate (NMDA)-receptor antagonist SDZ EAA 494 were investigated on memory and attention in humans. SDZ EAA 494 was administered either as single doses at a dose range of 1–50 mg, or as multiple doses over the course of 1 week at doses of 25 mg once or twice daily. Selected cognitive functions were assessed at baseline, 2 and 4 h after single dose administration, and at baseline, 2, 4 and 8 h on days 1 and 7 of multiple dose administration. The assessments included simple and complex reaction time tests to assess attention, and verbal, non-verbal and spatial memory tests with immediate and late recall. Verbal and non-verbal memory test performance was significantly impaired at a dose level of 50 mg after single administration, and of 25 mg twice daily after multiple administration, without concomitant significant impairment of reaction time. Spatial memory test performance was not significantly affected. The maximum effect occurred 2 h postmedication and was more pronounced after repeated administration. These results suggest that the inhibition of NMDA-receptors in humans may impair memory processes.

Key words

Memory Attention NMDA receptor Excitatory amino acid antagonist 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aebischer B, Frey P, Haerter H-P, Herrling PL, Mueller W, Olverman HJ, Watkins JC (1989) Synthesis and NMDA antagonistic properties of the enantiomers of 4-(3-phosphonopropyl)piperazine-2-carboxylic acid (CPP) and of the unsaturated analogue (E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (CPP-ene). Helv Chim Acta 72:1043–1047CrossRefGoogle Scholar
  2. Barnes CA (1990) Effects of aging on the dynamics of information processing and synaptic weight changes in the mammalian hippocampus. Prog Brain Res 86:89–104PubMedGoogle Scholar
  3. Bäumler G (1974) Lern- und Gedächtnistest: LGT-3. Hogrefe, GöttingenGoogle Scholar
  4. Bowen DM, Steele JE, Lowe SL, Palmer AM (1990) Tacrine in relation to amino acid transmitters in Alzheimer's disease. Adv Neurol 51:91–96PubMedGoogle Scholar
  5. Bunney WE, Bunney BG (1990) A view of psychopharmacology, neuroscience, and the major psychoses. In: Bunney WE, Hippius H, Laakmann G, Schmauß M (eds) Neuropsychopharmacology. Springer, Berlin, Heidelberg, New York, pp 11–23Google Scholar
  6. Carlsson A (1990) Perspectives on dopamine as a regulator of brain function. In: Bunney WE, Hippius H, Laakmann G, Schmauß M (eds) Neuropsychopharmacology. Springer, Berlin Heidelberg, New York, pp 2–10Google Scholar
  7. Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13:171–182CrossRefPubMedGoogle Scholar
  8. Difazio MC, Hollingsworth Z, Young AB, Penney JB (1992) Glutamate receptors in the substantia nigra of Parkinson's disease brains. Neurology 42:402–406PubMedGoogle Scholar
  9. Eccles JC (1990) Developing concepts of the synapses. J Neurosci 10:3769–3781PubMedGoogle Scholar
  10. Foster AC (1990) Physiology and pathophysiology of excitatory amino acid neurotransmitter systems in relation to Alzheimer's disease. Adv Neurol 51:97–102PubMedGoogle Scholar
  11. Ingram DK, Spangler EL, Iijima S, Ikari H, Kuo H, Greig NH, London ED (1994) Rodent models of Alzheimer dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis. Life Sci 55:2037–2049CrossRefPubMedGoogle Scholar
  12. Izquierdo I (1991) Role of NMDA receptors in memory. Trends Pharmacol Sci 12:128–129CrossRefPubMedGoogle Scholar
  13. Izquierdo I (1994) Pharmacological evidence for the role of long-term potentiation in memory. FASEB J 8:1139–1145PubMedGoogle Scholar
  14. Izquierdo I, Medina JH (1993) Role of the amygdala, hippocampus and entorhinal cortex in memory consolidation and expression. Braz J Med Biol Res 26:573–589PubMedGoogle Scholar
  15. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308Google Scholar
  16. Karobath M (1990) Pharmaceutical approaches to the treatment of dementia. In: Orgogozo JM, Gottfries CG (eds) Progress in dementia research. Parthenon Publishing, New Jersey, pp 99–109Google Scholar
  17. Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME (1984) Schizophrenia: a biochemical hypothesis. Nervenarzt 55:602–606PubMedGoogle Scholar
  18. Kristensen MO, Gutmann NC, Christensen JE, Ostergaard K, Rasmussen K (1993) Serum cobalamin and methyl malonic acid in Alzheimer dementia. Acta Neurol Scand 87:475–481PubMedGoogle Scholar
  19. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214PubMedGoogle Scholar
  20. Liang KC, Lin MH, Tyan YM (1993) Involvement of amygdalaN-methyl-d-aspartate receptor in long-term retention of an inhibitory avoidance response in rats. Chin J Physiol 36:47–56PubMedGoogle Scholar
  21. Malenka RC (1991) Postsynaptic events mediating LTP. In: Wheal H, Thompson A (eds) Excitatory amino acids and synaptic transmission. Academic Press, London, pp 303–314Google Scholar
  22. Oye I, Paulson O, Maurset A (1992) Effects of ketamine on sensory perception: evidence for a role ofN-methyl-d-aspartate receptors. J Pharmacol Exp Ther 260:1209–1213PubMedGoogle Scholar
  23. Pitts LH, McIntosh TK (1990) Dynamic changes after brain trauma. In: Visken PJ, Bruyn GW, Klawans HL, Braakman R (eds) Head injury. Elsevier, Amsterdam, pp 70–93Google Scholar
  24. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH (1994) Acute but not chronic activation of the NMDA-coupled glycine receptor withd-cycloserine facilitates learning and retention. Eur J Pharmacol 257:7–12CrossRefPubMedGoogle Scholar
  25. Rickard NS, Poot AC, Gibbs ME, Ng KT (1994) Both non-NMDA and NMDA glutamate receptors are necessary for memory consolidation in the day-old chick. Behav Neural Biol 62:33–40PubMedGoogle Scholar
  26. Rose SP (1991) The biochemistry of memory. Essays Biochem 26:1–12PubMedGoogle Scholar
  27. Scatton B (1993) The NMDA receptor complex. Fundam Clin Pharmacol 7:389–400PubMedGoogle Scholar
  28. Scatton B, Carter C, Dana C, Benavides J (1991) NMDA receptor antagonists: treatment of brain ischemia. Drug News Persp 4:89–102Google Scholar
  29. Siesjö BK, Memzawa H, Smith ML (1991) Neurocytotoxicity: pharmacological implications. Fundam Clin Pharmacol 5:755–767PubMedGoogle Scholar
  30. Sohlberg MM, Mateer CA (1987) Effectiveness of an attention-training program. J Clin Exp Neuropsychiatr 9:117–130Google Scholar
  31. Tamminga CA, Cascella N, Fakouhi TD, Herting RL (1992) Enhancement of NMDA-mediated transmission in schizophrenia: effects of milacemide. In: Meltzer HY (ed) Novel antipsychotic drugs. Proceedings of a symposium held in San Juan. Raven Press, New York, pp 171–177Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • S. Rockstroh
    • 1
  • M. Emre
    • 1
  • R. Pokorny
    • 1
  • A. Tarral
    • 2
  1. 1.Sandoz Pharma LtdBaselSwitzerland
  2. 2.Laboratorires SandozRueil Malmaison CedexFrance

Personalised recommendations